Acrivon Therapeutics (ACRV) insider offloads 400 shares for taxes

Rhea-AI Filing Summary

Acrivon Therapeutics, Inc. (ACRV) reported that Chief Development Officer Erick Gamelin had 400 shares of common stock sold on August 18, 2026 at $2.01 per share. According to the disclosure, these shares were sold automatically to satisfy mandatory tax withholding upon vesting of restricted stock units, leaving him with 52,592 shares held directly.

Insider Trade Summary

Net Seller: 400 shares

Net Sell 1 txn

Insider Gamelin Erick

Role Chief Development Officer

Sold 400 shs ($804.00)

Type	Security	Shares	Price	Value
Sale	Common Stock F1	400	$2.01	$804.00

Holdings After Transaction: Common Stock — 52,592 shares (Direct)

Footnotes (1)

1. F1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

Key Figures

Shares sold: 400 shares Sale price per share: $2.01 per share Shares held after transaction: 52,592 shares

3 metrics

Shares sold 400 shares Non-derivative common stock transaction on August 18, 2026

Sale price per share $2.01 per share Price for the 400 shares sold on August 18, 2026

Shares held after transaction 52,592 shares Direct holdings of Erick Gamelin following the reported sale

Key Terms

restricted stock units, mandatory tax withholding, non-derivative

3 terms

restricted stock units financial

"upon vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

mandatory tax withholding financial

"to satisfy the mandatory tax withholding requirement"

non-derivative financial

"transaction coded as a sale of non-derivative securities"

FAQ

What insider transaction did ACRV report for Erick Gamelin on this Form 4?

The filing reports that Erick Gamelin had 400 shares of Acrivon Therapeutics, Inc. common stock sold on August 18, 2026 at $2.01 per share, in a transaction coded as a sale of non-derivative securities.

Why were Erick Gamelin’s ACRV shares sold in this Form 4 transaction?

The footnote states the 400 shares were sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units, indicating the sale was for tax withholding rather than a discretionary open-market liquidation.

How many ACRV shares does Erick Gamelin hold after this reported transaction?

After the reported tax-withholding sale, Erick Gamelin holds 52,592 shares of Acrivon Therapeutics, Inc. common stock directly, as stated in the post-transaction holdings field of the Form 4.

What price was received per share in Erick Gamelin’s ACRV stock sale?

The Form 4 reports a transaction price of $2.01 per share for the 400 shares of Acrivon Therapeutics, Inc. common stock that were sold to satisfy mandatory tax withholding upon RSU vesting.

Was Erick Gamelin’s ACRV transaction under a Rule 10b5-1 trading plan?

The document-level Rule 10b5-1 checkbox is marked false, indicating the filing does not affirm that this transaction was made pursuant to a Rule 10b5-1 trading plan. The footnote instead explains the sale as mandatory tax withholding on RSU vesting.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/20/2026 - 04:09 PM Accepted by SEC EDGAR 08/20/2026 - 04:08 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gamelin Erick

(Last) (First) (Middle)

C/O ACRIVON THERAPEUTICS, INC.

480 ARSENAL WAY, SUITE 100

(Street)

WATERTOWN MASSACHUSETTS 02472

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Acrivon Therapeutics, Inc. [ ACRV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		400	D	$2.01	52,592	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares sold automatically to satisfy the mandatory tax withholding requirement upon vesting of restricted stock units.

	/s/ Adam D. Levy, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)